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Abstract: The poor healing potential of tendons is still a clinical problem, and the use of Platelet Rich
Plasma (PRP) was hypothesized to stimulate healing. As the efficacy of PRPs remains unproven,
platelet lysate (PL) could be an alternative with its main advantages of storage and characterization
before use. Five different blood products were prepared from 16 male donors: human serum,
two PRPs (Arthrex, (PRP-ACP); RegenLab (PRP-BCT)), platelet concentrate (apheresis, PC), and PL
(freezing-thawing destruction of PC). Additionally, ten commercial allogenic PLs (AlloPL) from
pooled donors were tested. The highest concentration of most growth factors was found in AlloPL,
whereas the release of growth factors lasted longer in the other products. PRP-ACP, PRP-BCT,
and PC significantly increased cell viability of human tenocyte-like cells, whereas PC and AlloPL
increased Col1A1 expression and PRP-BCT increased Col3A1 expression. MMP-1, IL-1β, and HGF
expression was significantly increased and Scleraxis expression decreased by most blood products.
COX1 expression significantly decreased by PC and AlloPL. No clear positive effects on tendon cell
biology could be shown, which might partially explain the weak outcome results in clinical practice.
Pooled PL seemed to have the most beneficial effects and might be the future in using blood products
for tendon tissue regeneration.
Keywords: platelet rich plasma; platelet lysate; tenocyte-like cells; tendon healing; cell culture
1. Introduction
Tendon healing is limited due to the poor vascularity and intrinsic healing capacity [1–3].
To address this deficit, several therapeutic approaches were investigated in order to optimize tendon
healing processes. Over the last decade, different platelet preparations were tested regarding their
stimulating effect on musculoskeletal tissue healing [4,5], showing that PRP can enhance human bone,
muscle, and tendon cell proliferation as well as the collagen I gene expression and matrix synthesis
Int. J. Mol. Sci. 2018, 19, 212; doi:10.3390/ijms19010212 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2018, 19, 212 2 of 18
of tenocytes in vitro [6–8]. Furthermore, PRP has been shown to promote tendon healing in vivo
using rodent Achilles and Patellar tendon pathology models [9–12]. Platelet Rich Plasma (PRP) or
other blood preparations might offer the possibility to promote tendon healing without having any
negative side effects and are low in costs. The idea that PRP can promote tissue healing is based
on the high content of growth factors in the alpha granula of the platelets like transforming growth
factor β (TGF-β), platelet-derived growth factor (PDGF), insulin-like growth factor 1 (IGF-1), vascular
endothelial growth factor (VEGF), fibroblast growth factor (FGF), and others, which are known to
trigger or even be involved in angiogenesis and tissue regeneration [13]. However, the efficacy of
PRP for clinical applications remain unproven [14,15], but positive effects on pain relief and chronic
impairments were reported [16–22]. Existing studies often lack appropriate controls to validate the
findings. The variable outcome data may be due to the high individual differences of each patients PRP
composition regarding platelet number and therefore concentration of growth factors. Additionally,
methods for preparation, activation of platelets, surgical application and treatment volume are highly
variable [23–25]. Platelet concentrate (PC) is a standard blood product in transfusion medicine, which is
prepared by apheresis. It contains ten times more platelets compared to PRP, nearly no other blood
cells and the platelet content is nearly independent from the donors age and sex. Therefore, we choose
PC as our source material to prepare platelet lysate (PL), a cell free supernatant rich in growth factors,
which are released from the platelets after freeze-thawing disruption of the PC [26]. PL is already
clinically used for the treatment of different regenerative pathologies of wounds and eye ulcers [27–30].
Additionally, in vitro studies showed the potential of PL to enhance wound healing processes [31,32].
A further advantage of PL compared to conventional PRPs is that it can be stored frozen and therefore
used for consecutive applications. Furthermore, it can be analyzed for growth factor content and other
characteristics before its use to standardize the product. As PC is supposed for allogenic use with an
already established safety/testing system, an allogenic use for PL might also be conceivable. Although
PRP and modifications like PL are intensively investigated during the last years, existing studies
mostly focus on PL as a humane based cell culture supplement for preclinical cell propagation [33–35].
Furthermore, studies mainly investigated the impact of PL on humane MSC’s, chondrocytes or corneal
endothelium cells [36–39]. To our knowledge, only one study exists, which investigated the impact of
PL on tenocytes in vitro [40]. Furthermore, there is a lack of studies that compared PLs to standard
PRPs regarding their growth factor content as well as their stimulatory potential on human tenocytes
of the rotator cuff.
Therefore, it was the aim of the present study to characterize five different platelet-based blood
products including two PLs, two PRPs, and PC and compare their capacity to affect cell viability and
gene expression of several markers related to tendon extracellular matrix, modeling and remodeling,
inflammation, and pain. The hypothesis was that PC and both PLs would have advantageous effects
compared to standard PRP preparation due to their increased platelet content and possibly increased
growth factor content.
2. Results
Blood from 16 donors was taken, and all four different blood products were produced from the
blood of each donor to allow the comparison.
2.1. Characterization of Blood Products
The concentration of platelets and leukocytes was quantified in the whole blood and the blood
products PRP-ACP, PRP-BCT, and PC and from each individual donor. The strongest enrichment
of platelets was found in the PC (3.8 fold higher than blood) followed by PRP-ACP (1.9 fold higher
than blood). Surprisingly, PRP-BCT had a reduced platelet count (0.7 fold lower compared to blood).
Significant differences between the groups are shown in Figure 1A. Leukocytes were significantly
reduced in all blood products compared to the whole blood. PRP-BCT showed a significantly increased
leukocyte content compared to PRP-ACP and PC (Figure 1B). PCs used to produce pooled AlloPL
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contained between 500–2045 × 103 platelets/µL according to manufacturer information (data sheet)
and were leukocyte depleted (<5 leukocytes/µL).
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Figure 1. Platelet (A) and leukocyte (B) concentration in Arthrex, (PRP-ACP), RegenLab (PRP-BCT), 
and platelet concentrate (PC) compared to whole blood. (A) Platelet concentration was significantly 
higher in PRP-ACP and PC group and lower in the PRP-BCT group. (B) Leukocyte concentration was 
significantly reduced in all groups. °,* indicate outliers, n = 16 individual donors, all blood product 
were produced from each donor. 
Growth factor quantification was performed for all blood products and human serum (HS) as 
control (Figure 2). bFGF concentration was significantly increased in the PC group compared to HS 
control, PRP-BCT and PL group. Additionally, AlloPL showed a significantly higher bFGF 
concentration compared to all other groups except PC. HGF concentration did not differ between the 
blood products and the HS, while IGF-1 concentration was significantly decreased in the AlloPL 
group compared to all other groups. PDGF-AB and TGF-β1 showed a similar pattern with a 
decreased concentration in the PRP-BCT group compared to all other groups and an increased 
concentration in the PC and AlloPL group compared to all other groups. The TGF-β1 concentration 
did not differ between PC and AlloPL. The concentration of VEGF was significantly higher in the 
AlloPL group compared to HS, PRP-BCT and PL. The outliners in bFGF, HGF, and VEGF 
concentration came from the same two blood donors. 
Negative moderate correlation was found for the platelet concentration with the leukocyte 
concentration (rs: −0.608). Additionally, a strong positive correlation of platelet concentration was 
seen with PDGF-AB and TGF-β1 (rs: 0.850 and rs: 0.837). 
In the release experiment, the blood product was placed into a cell culture well and the growth 
factor concentrations secreted into the medium over a five-day period were evaluated (Figure 3). 
bFGF, HGF, and VEGF concentrations were below the detection limit of the assays in most cases. 
Only in the AlloPL group mean amounts of 21.7 ± 2.1 pg/mL bFGF and 56.2 ± 64.1 pg/mL HGF were 
found after 1 h. IGF-1, PDGF-AB and TGF-β1 were released from PRP-ACP, PRP-BCT, PC and PL for 
at least 2 days and in some cases also over the entire period of five days. From AlloPL the growth 
factors were released only at the early time points until 4 h. PRP-ACP reached the highest final 
concentration of IGF-1 followed by PC and PRP-BCT. PDGF-AB and TGF-β1 showed a comparable 
release pattern. PC reached the highest final concentrations of PDGF-AB and TGF-β1 followed by 
AlloPL, PRP-ACP, and finally PL and PRP-BCT. 
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Growth factor quantification was performed for all blood products and human serum (HS)
as control (Figure 2). bFGF concentration was significantly increased in the PC group compared
to HS control, PRP-BCT and PL group. Additionally, AlloPL showed a significantly higher bFGF
concentration compared to all other groups except PC. HGF concentration did not differ between
the blood products and the HS, while IGF-1 concentration was significantly decreased in the AlloPL
group compared to all other groups. PDGF-AB and TGF-β1 showed a similar pattern with a decreased
concentration in the PRP-BCT group compared to all other groups and an increased concentration
in the PC and AlloPL group compared to all other groups. The TGF-β1 concentration did not differ
between PC and AlloPL. The concentration of VEGF was significantly higher in the AlloPL group
compared to HS, PRP-BCT and PL. The outliners in bFGF, HGF, and VEGF concentration came from
the same two blood donors.
Negative moderate correlation was found for the platelet concentration with the leukocyte
concentration (rs: −0.608). Additionally, a strong positive correlation of platelet concentration was
seen with PDGF-AB and TGF-β1 (rs: 0.850 and rs: 0.837).
In the release experiment, the blood product was placed into a cell culture well and the growth
factor concentrations secreted into the medium over a five-day period were evaluated (Figure 3). bFGF,
HGF, and VEGF concentrations were below the detection limit of the assays in most cases. Only in
the AlloPL group mean amounts of 21.7 ± 2.1 pg/mL bFGF and 56.2 ± 64.1 pg/mL HGF were found
after 1 h. IGF-1, PDGF-AB and TGF-β1 were released from PRP-ACP, PRP-BCT, PC and PL for at least
2 days and in some cases also over the entire period of five days. From AlloPL the growth factors were
released only at the early time points until 4 h. PRP-ACP reached the highest final concentration of
IGF-1 followed by PC and PRP-BCT. PDGF-AB and TGF-β1 showed a comparable release pattern.
PC reached the highest final concentrations of PDGF-AB and TGF-β1 followed by AlloPL, PRP-ACP,
and finally PL and PRP-BCT.
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Figure 2. Growth factor quantification in the blood products PRP-ACP, platelet rich plasma (PRP), 
RegenKit-Blood Cell Therapie (BCT), PC, platelet lysat (PL), Allogenic platelet lysate (AlloPL), and 
human serum (HS) control measured by ELISA. (A) Basic fibroblast growth factor (bFGF) 
concentration was higher in PC compared to HS, PRP-BCT, and PL as well as in AlloPL compared to 
HS, both PRPs, and PL. (B) Hepatocyte growth factor (HGF) concentration was not significantly 
changed. C) Insulin-like growth factor 1 (IGF-1) concentration was decreased in the AlloPL group. 
(D) Platelet-derived growth factor (PDGF-AB) and (E) transforming growth factor β (TGF-β1) 
concentration was lower in the PRP-BCT group and higher in the PC and AlloPL group compared to 
all other groups and for TGF-β1 concentration except for PC and AlloPL. (F) Vascular endothelial 
growth factor (VEGF) concentration was increased in the AlloPL group compared to HS, PRP-BCT, 
and PL. °,* indicate outliers, n = 16, except for AlloPL n = 10. 
Figure 2. Growth factor quantification in the blood products PRP-ACP, platelet rich plasma (PRP),
RegenKit-Blood Cell Therapie (BCT), PC, platelet lysat (PL), Allogenic platelet lysate (AlloPL),
and human serum (HS) control measured by ELISA. (A) Basic fibroblast growth factor (bFGF)
concentration was higher in PC compared to HS, PRP-BCT, and PL as well as in AlloPL compared
to HS, both PRPs, and PL. (B) Hepatocyte growth factor (HGF) concentration was not significantly
changed. (C) Insulin-like growth factor 1 (IGF-1) concentration was decreased in the AlloPL group.
(D) Platelet-derived growth factor (PDGF-AB) and (E) transforming growth factor β (TGF-β1)
concentration was lower in the PRP-BCT group and higher in the PC and AlloPL group compared
to all other groups and for TGF-β1 concentration except for PC and AlloPL. (F) Vascular endothelial
growth factor (VEGF) concentration was increased in the AlloPL group compared to HS, PRP-BCT,
and PL. ◦ ,* indicate outliers, n = 16, except for AlloPL n = 10.
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Figure 3. Cumulative growth factor release from blood products into the medium measured after 1, 
4, 24, 48, and 120 h by ELISA. IGF-1 (A), PDGF-AB (B), and TGF-β1 (C) were release only over 4 h by 
AlloPL but constantly over 2–5 days by the other blood products. The release experiments were 
performed exemplarily for n = 4 donors. 
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ACP (Figure 4B). In the group of the matrix degrading enzymes, the expression of the collagenase 
MMP-1 was significantly increased in hTLCs by all blood products compared to the HS control, while 
additionally the PC stimulated cells showed an increased expression compared to both PRPs and PL. 
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while additionally the PC stimulated cells showed an increased expression compared to both PRPs
and PL. AlloPL stimulation significantly increased MMP-1 expression compared to PL. The expression
of the collagenase MMP-13 significantly decreased after PC stimulation in the hTLCs (Figure 4C).
No alterations of the expression of the gelatinases MMP-2 and MMP-9 could be observed after
stimulation (Figure 4D).
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products compared to HS control with significantly highest expression in the PC group and MMP-13 
decreased by PC stimulation. (D) MMP-2 and MMP-9 expression did not change. # marks significant 
differences between the HS control and the blood products and the spanning line between the 
individual groups. °,* indicate outliers. PRP-ACP: n = 11, PRP-BCT: n = 12, PC: n = 15, PL: n = 14, 
AlloPL: n = 10. N-numbers varied due to clotting events in the well, which leads to the loss of cells. 
Figure 4. Cell viability and relative gene ex r te-like ce ls (hTLCs) stimulated
with blood products compared to HS control (line) measured by qPCR using ∆Ct method wit efficiency
corre tion normalized t 18S rRNA. (A) Cell viability was significantly increased by both PRPs and PC
compared to HS control. (B) Col1A1 expressi n was significantly increased b PC and AlloPL group
compared to HS ntrol and in AlloPL c mpared to PL. Col3A1 expression was significantly increased
by PRP-BCT and scleraxis (SCX) expression decreased in all groups except PRP-ACP compared to
HS control. (C) MMP-1 expression significantly increased by all blood products compared to HS
control with significantly highest expression in the PC group and MMP-13 decreased by PC stimulation.
(D) MMP-2 and MMP-9 expression did not change. # marks significant differences between the HS
control and the blood products and the spanning line between the individual groups. ◦ ,* indicate
outliers. PRP-ACP: n = 11, PRP-BCT: n = 12, PC: n = 15, PL: n = 14, AlloPL: n = 10. N-numbers varied
due to clotting events in the well, which leads to the loss of cells.
Int. J. Mol. Sci. 2018, 19, 212 7 of 18
The stimulation of hTLCs with all blood products resulted in a significantly increased expression
of the pro-inflammatory cytokine IL-1β. The strongest but also highly variable increase was observed
after PRP-BCT incubation (Min-Max relative gene expression: 0.87–362.45), which was significantly
different compared to the PC, PL and AlloPL group (Figure 5A). The TNF-α expression was not
affected by the stimulation with the blood products and IL-6 expression was decreased by AlloPL
application compared to the PRP-BCT group. The expression of the anti-inflammatory cytokine IL-10
revealed no or negligible amounts of RNA in the analyzed hTLCs. The pain related factors COX1,
COX2 and HGF were regulated in a varying manner (Figure 5B). The stimulation of the hTLCs with the
blood products PC and AlloPL significantly decreased the COX1 expression, while COX2 expression
was not affected by treatment with the blood products. HGF expression was significantly increased
compared to HS control by all blood products except for PRP-BCT. PRP-BCT stimulation additionally
showed a decreased HGF expression in the hTLCs compared to all other blood products.
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Figure 5. Relative g n expression in hTLCs sti l ith bl od products compared to HS c ntrol
(line) measured by qPCR using ∆ t method with efficiency correction normalized to 18S rRNA.
(A) IL-1β expression was significantly increased by all blood products with significantly highest
expression in PRP-BCT group (higher outliners were cut off). TNF-α was not altered in all groups.
IL-6 was decreased in the AlloPL group compared to PRP-BCT. (B) COX1 expression was significantly
decreased in PC and AlloPL group and COX2 expression did not change. HGF expression was
significantly increased by all products except PRP-BCT. # marks significant differences between the
HS control and the blood products and the spanning line marks significant differences between the
individual groups. ◦ ,* indicate outliers. PRP-ACP: n = 11, PRP-BCT: n = 12, PC: n = 15, PL: n = 14,
AlloPL: n = 10. N-numbers varied due to clotting events in the well, which leads to the loss of cells.
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A positive moderate correlation was found for MMP-1 and HGF expression with the platelet
concentration (MMP-1: rs = 0.513, p ≤ 0.001; HGF: rs = 0.648, p ≤ 0.001), and a moderate negative
correlation was observed with the leukocyte content of the blood products (MMP-1: rs = −0.626,
p ≤ 0.001; HGF: rs = −0.578, p ≤ 0.001). For the HGF expression, a moderate correlation with the
TGF-β1 concentration could be observed (rs = 0.539, p ≤ 0.001).
3. Discussion
The aim of the present study was to compare the effect of five different platelet-based blood
products on tenocytes of the human rotator cuff to better understand their possible effect in clinical
use. Next to the commercially available PRPs PRP-ACP and PRP-BCT and a platelet concentrate (PC)
obtained by apheresis, the focus of the present study was to analyze two platelet lysates, one conducted
from PC (PL) and one commercially available pooled PL from different donors (AlloPL). The two PLs
have application advantages such as characterization before use and storage for repeated use.
Our hypothesis, that products with a higher platelet content like PC and its preparation PL as well
as the pooled AlloPL would have advantageous effects compared to standard PRP preparations due
to their possibly increased growth factor content, has to be partly rejected. Although PC and AlloPL
showed an increased content of the growth factors TGF-β1, VEGF, PDGF-AB, and bFGF, this was not
accompanied by highly increased stimulation of tenocytes viability and gene expression of extracellular
matrix proteins. However, the stronger effects on HGF expression as well as the downregulation of
COX1 expression seen after stimulation with PC and AlloPL suggest stronger effects on pain relief and
inflammation compared to standard PRP’s.
Surprisingly, PL showed significantly different results, especially compared to PC and AlloPL,
although the initial platelet concentration was comparable in the three products. Whereas AlloPL
showed the highest growth factor concentrations except for IGF-1 within all blood products, PL showed
relatively low concentrations. The preparation method of both PLs might be the reason for the different
growth factor contents. First, AlloPL was prepared from PCs, which were stored up to six days before
further preparation. During that storage time, further platelets might be activated and produced
growth factors and therefore increased growth factor concentration in the AlloPL after platelet lysis.
The positive influence of longer storage of PLs on the concentration of most growth factors and
the decrease in IGF-1 concentration was shown previously [41]. Furthermore, PL was produced by
a freezing step at −80 ◦C compared to −30 ◦C for the AlloPL, which might have destroyed some
growth factors and reduced their impact. The −80 ◦C freezing temperature was chosen in establishing
experiments to be the best temperature to reduce clotting events in the well [42].
A strength of the study is the preparation of all four blood products and HS (except of AlloPL)
from the same 16 donors. This allows a direct comparison of the results and reduces the donor
dependent variations. However, variations in the growth factor content due to the donors are quite
obvious: distinct variations and outliners as shown in Figure 2. Analyzing the in vitro release of the
growth factors, AlloPL showed a burst release of growth factors into the medium until 4 h, whereas
a more continuous release was observed for the other blood products. This might indicate that in
AlloPL all platelets were destroyed and therefore released their growth factors, whereas in PL the
freezing process might have been not sufficient to destroy all platelets to release their growth factors.
However, the different release kinetics could also be caused by different clotting intensities of the
blood products in the transwell insert, whereas a denser clot as seen for PRP-ACP, PRP-BCT, PL, and
PC leads to a more continuous release compared to AlloPL. This confirms other studies demonstrating
the influence of PRP clot characteristics on the growth factor release pattern [43,44]. A comparable
release pattern was observed by other authors investigating the release from PRP clots [43], whereas
the release pattern from liquid PRPs is more comparable to the present AlloPL [45]. It was speculated
that a burst release of growth factors decreases the therapeutic efficacy of PRPs [43]. Unfortunately,
this speculation cannot be proved by the in vitro study. The half-life of the growth factors in vitro and
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in vivo is not comparable and it is expected that it is shorter in vivo. Therefore, the initial release from
AlloPL is sufficient to stimulate the cells, as demonstrated within the present study.
As expected platelet content was highest in PC followed by ACP and BCT. Surprisingly, the
PRP-BCT was not able to reach a platelet count comparable to the whole blood (concentration factor:
0.7). A handling mistake can be excluded, as we were instructed by the company at the first PRP-BCT
preparations. In PRP-ACP, increased platelet concentrations were found (concentration factor: 1.8),
which was comparable to other studies [7,46]. Another study confirmed variations in the platelet
content between PRPs from Arthrex and Regenlab with, in contrast, a higher concentration factor in
the PRP from Regenlab compared to Arthrex [47]. The varying findings might be a result of variations
in the preparation method, such as anticoagulant as used for the Arthrex PRP preparation in this study,
whereas our PRP-ACP was produced without anticoagulate, as it is performed in clinical practice in
our hospital.
The strong variations in platelet and growth factor concentrations between the blood products
do only weakly affect the cell viability or gene expression of the hTLCs. The high growth factor
concentrations in the PC and AlloPL did not result in highly increased cell viability, which was
increased strongest by both PRPs and PC. This underlines that a high platelet or growth factor
concentration, especially for those growth factors regulating cell growth, did not result in highly
increased cell viability and can have stagnating or inhibitory effects, as also reported by other
authors [48–52]. A comparable positive effect of PRP-ACP on the cell proliferation of tenocytes
was previously shown [7].
Also, the expression data weakly mirror the strong variation in platelet and growth factor
concentration. Only the Col1A1 and MMP-1 expression was increased the most by PC and AlloPL.
Other studies also showed that the regulation of Col1A1 expression after treatment of tenocytes with
platelet based blood products seems to be highly dependent on the concentration and activation
of the product and the used negative control and was found to be increased, not regulated or
decreased [8,50–52]. Col3A1 is associated with the reduction of biomechanical properties of the
tendon [53] and the increase after stimulation with PRP-BCT might negatively affect the tendon
healing outcome. Comparable to PRP effects on Col1A1 expression, varying results were reported
for Col3A1 with increased and decreased Col3A1 expression after stimulation of tenocytes with
different platelet-based blood products [8,51,52]. The expression of the tendon related transcription
factor SCX was in the present study decreased by all blood products except for PRP-ACP. SCX is
important for tendon formation and development [54], and it was shown that SCX transduction of
human MSCs led to their reprogramming into tendon progenitors [55]. A decrease might therefore
lead to a dedifferentiation of the hTLCs and might in vivo result in the formation of a less organized
tendon structure as demonstrated for Scx−/−mutant mice [56]. A further study stimulating tenocytes
with blood products found a comparable decrease in SCX expression [8], whereas others found no
regulations or an increased SCX expression [48,50,51]. The higher platelet concentrations and the
comparison to 1% or 2% FCS control instead of a 10% HS control might account for the contrary
findings, because the higher serum control itself leads to a stronger stimulating effect. The expression
of the MMPs differed in the present study. The collagenase MMP-1 was strongly increased by all groups,
whereas MMP-13 and the gelatinases showed no changes or a decreased expression. Comparable
results were previously found for MMP-1 and MMP-13 expression after stimulation of tenocytes
with blood products [52], whereas in contrast, an increased MMP-2 and MMP-9 enzyme activity was
found [48]. In the present study, only expression and no enzyme activities were tested, which impede
the direct comparison of the results. MMPs are important for the modeling and remodeling of the
extracellular matrix of tendons and the balance between MMPs and their natural inhibitors; the Tissue
Inhibitors of Metalloproteases (TIMPs) are important to maintain tendon homeostasis [57]. The strong
increase in MMP-1 expression might lead to an imbalanced MMP/TIMP ratio and might therefore
negatively affect the tendon healing process.
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The leukocyte concentration in the present study was higher in the PRP-BCT group compared to
the PRP-ACP and PC group. This confirms another study showing that PRP-ACP has a lower amount of
leukocytes compared to PRP-BCT. However, the authors found a leukocyte concentration factor of 1.52
in the PRP-BCT compared to whole blood, whereas we observed for both PRPs a leukocyte-reduction
compared to whole blood (concentration factor PRP-ACP: 0.026; PRP-BCT: 0.13) [47]. Even this
underlines that, despite the compliance with the manufacturer’s instructions, the PRP composition
highly depends on the individual preparation method. The role of leukocytes in PRP is still under
debate. One study claims an important antimicrobial role of leukocytes [58], while another study refers
to a negative relationship between leukocytes and healing [59]. With the analysis of the expression of
inflammatory cytokines (IL-1β, TNF-α, IL-6, IL-10) in the stimulated hTLCs, we aimed to investigate
the effect of the blood products on inflammatory processes. IL-1β expression was increased by all
blood products, but strongest by PRP-BCT, which also showed the highest leukocyte concentration.
Additionally, a correlation between leukocytes and the IL-1β concentration could be observed. We did
not analyze the concentration of cytokines in the blood products itself, but the presence of IL-6 and
TNF-α in blood products was shown previously [50]. Additionally, the IL-1β concentration was
linked to neutrophils and monocytes in PRPs [46]. As shown in a cell culture study, the stimulation
of tenocytes with TNF-α led to an up-regulation of IL-1β expression [60]. The present results might
indicate that leukocytes and/or cytokines in the blood products induce pro-inflammatory processes
in the cell. It stays questionable if this is positive or negative for the tendon healing process and the
later outcome.
The published PRP studies demonstrate the complexity of comparison between each other, due
to different preparation methods, platelet/growth factor concentration, activation and stimulation
time and the used negative control (1% FCS, 2% FCS, 10% FCS, and 10% human serum). Most cell
culture studies claim positive results of different PRPs but so far the clinical observations are restrained.
Most authors reported on no positive effects of PRPs on the functional clinical outcome after tendon
repair [61–64]. However, a positive effect on pain reduction was observed [21,65]. Therefore, also the
expression of the pain associated factors COX1, COX2, and HGF were analyzed. Zhang et al. claimed an
anti-inflammatory effect of PRP due to the presence of HGF. And this in turn was hypothesized to result
in pain reduction by down regulation of COX1 and -2, prostaglandin (PGE), and PGE synthase [66].
The anti-inflammatory effect of PRP cannot be confirmed by the present results, due to the overall
increased expression of the pro-inflammatory cytokine IL-1β. However, the COX1 expression was
significantly decreased by PC and AlloPL in the hTLCs. Additionally, the HGF expression was induced
by application of all blood products except PRP-BCT. This might result in pain reduction when it
comes to PRP treatment in clinical practice.
As a limitation of the study, it has to be mentioned that only hTLCs of old donors (67–72 years)
were used to study the effect of the blood products. As we could previously show that the biological
characteristics and the stimulation potential after BMP-2/-7 application of hTLCs is decreased with
age [67], the use of hTLCs from younger donors could have demonstrated different results. However,
old donors were chosen as they represent the typical patient cohort for degenerative rotator cuff
ruptures, where the application of blood products might be a treatment option. Another limitation
is the missing evaluation of the sex factor in the current study, as we only treated male cells with
male blood products. Xiong et al. recently compared PRPs from male and female donors and
found significant differences regarding growth factor content between male and female PRPs [68].
To reduce variabilities, we decided to use only male cells and blood products. However, possible
sex based differences are an interesting topic and should be investigated in future studies. We are
aware that conclusions drawn from the present results are speculative regarding any in vivo effect
e.g., with regards to inflammation, but might be very useful to understand the role of different blood
products on the cellular level.
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4. Materials and Methods
4.1. Preparation of Human Blood Products
All blood products except for the allogenic platelet lysate (AlloPL) were obtained from 16 healthy
male donors with a mean age of 42 years (range 30–50 years). The blood was taken in the Institute of
Transfusion Medicine (Berlin, Germany) during routinely blood donation. All donors gave their written
informed consent for the production of blood products and usage for the present study (EA1/038/14).
The platelet concentration was automatically quantified with the ABX penta XL 80 (Horiba medical,
Grabels, France) system and the leukocyte concentration was manually quantified using a Nageotte
counting device.
4.2. Platelet Concentrate (PC)/Plasma Lysate (PL)/Allo-PL Preparation
Platelet concentrate (PC) was produced in the Institute of Transfusion Medicine (Berlin, Germany)
using a Trima Accel® (TERUMO BCT, Inc., Lakewood, CO, USA) automated blood collection system
with a leukocyte reduction system chamber. The PC was used freshly after preparation.
Platelet lysate (PL) was produced from PC by a freezing and thawing step. A total of 5 mL PC
was frozen a −80 ◦C for 30 min to destroy the platelets and release the growth factors. After thawing
at 37 ◦C in the water bath, the lysate was centrifuged at 1600× g for 10 min to separate the cell debris.
The supernatant was used for cell stimulation.
Allogenic platelet lysate (AlloPL) was obtained from the Institute for Clinical Transfusion Medicine
and Immunogenetics, Ulm, Germany. The AlloPL was prepared as described by Fekete et al. from a
platelet pool from up to 100 donors and stored at −30 ◦C [69]. The frozen AlloPL was shipped to our
laboratory. Before use the AlloPL was thawed at 37 ◦C in the water bath and centrifuged at 1800× g
for 10 min. A total of 10 different AlloPLs were included in the study. The lower number of AlloPL
resulted from the expectation of lower variation in the pooled blood product compared to the blood
products obtained from individual donors.
4.3. Standard PRP Preparations and Human Serum (HS) Control
Platelet rich plasma (PRP) was produced using two different commercially available devices.
Autologous conditioned plasma (ACP double syringe system, Arthrex, Germany) was used to produce
PRP-ACP according to the manufacturer´s instructions. A total of 10 mL blood was taken into the
double syringe without anticoagulate and centrifuged at 400× g for 5 min in the Rotofix 32A centrifuge
(Hettich, Germany). The upper separated PRP-ACP was subtracted with the inner syringe and used
for hTLC stimulation. PRP-BCT was produced with the RegenKit-Blood Cell Therapie (BCT, Regenlab,
Le Mont-sur-Lausanne, Switzerland) according to the manufacturer’s instructions. Therefore, 8 mL of
blood were directly collected into the RegenKit-BCT tubes containing sodium citrate as anticoagulate
and centrifuged at 1500× g for 5 min. Afterwards the tubes were slowly pivoted 15 times and the
supernatant (PRP-BCT) used for cell stimulation.
Human serum (HS) served as negative control and was produced using a commercially available
serum tube. The blood was left to clot for 30 min at room temperature before centrifuged for 10 min at
1500× g.
4.4. Growth Factor Quantification
For further characterization of the blood products, the concentration of the growth factors basic
fibroblast growth factor (bFGF), platelet derived growth factor (PDGF-AB), transforming growth
factor β (TGF-β1), hepatocyte growth factor (HGF) (ELISA recognizes VEGF121, VEGF165, VEGF165b),
and insulin-like growth factor 1 (IGF-1) were determined using commercially available sandwich
ELISAs (DuoSet ELISA, R&D Systems, Wiesbaden, Germany). The frozen blood products were thawed
and centrifuged for 5 min at 1600× g. The supernatant was used for ELISA. ELISAs were performed
according to the manufacturer’s instructions. For the optimal release of the growth factors IGF-1 and
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TGF-β1, the blood products had to be activated using HCL according to the manufacturer instructions
and were afterward neutralized using Tris-Base or NaOH/Hepes, respectively.
4.5. Growth Factor Release from Blood Products
The release of growth factors from the blood products over 120 h was analyzed in vitro
(n = 4 donors). Therefore, the experimental setup was done as described for stimulation experiments,
but without cells. After 1 h, 2 h, 4 h, 24 h, 48 h, and 120 h the entire medium was collected and replaced
by fresh experimental medium (medium + HS). The elution samples were stored at −20 ◦C until
quantified by sandwich ELISA for the growth factors FGF, HGF, IGF-1, PDGF-AB, TGF-β1, and VEGF.
Experimental medium only served as control.
4.6. Human Tenocyte-Like Cells
Human tenocyte-like cells (hTLCs) were obtained from torn supraspinatus tendons from four
male patients with a mean age of 69.5 years (67–72 years) undergoing arthroscopic or open surgery
for rotator cuff repair of chronic ruptures. All samples were collected according to a standardized
protocol and were grasped 3 to 5 mm from the torn proximal tendon edge. Prior to biopsy, all patients
gave their written informed consent and the study was approved by the local authorities (EA/060/09).
After collagenase digestion, hTLCs were grown in DMEM/HAM’s F12 (1:1) medium with 10% Fetal
calf serum (FCS) and 1% Penicillin/Streptomycin (P/S). Cells were trypsinized, pooled, and frozen
until used for stimulation experiments. The hTLCs were harvested according to a previously
established protocol [70], which proved the isolation of cells with tenocyte-like properties, such as
expression of tendon related genes and a distinct expression pattern compared to other cells of the
musculoskeletal system.
4.7. Cell Stimulation
A total of 1 × 104 vital cells per well of the pooled hTLCs in passage 2 were seeded into a 24-well
plate and incubated for two days in normal growth medium (DMEM/HAMs F-12, 10% FCS, 1% P/S).
At day 0 of stimulation, an Alamar Blue test (Biozol, Germany) was performed according to the
manufacturer’s instructions to analyze the metabolic activity of the cells and is according to the manual
termed as “cell viability” in the text. Afterwards, 800 µL of experimental medium (DMEM/HAMs
F-12, 10% HS, 1% P/S) was pipetted into each well. The hTLCs of the negative control received 1 mL of
experimental medium. A total of 100 µL of the particular blood products (PC, PL; PRP-ACP, PRP-BCT,
AlloPL) and 100 µL experimental medium were mixed and incubated in polycarbonate transwells
with 0.4 µm pore size (Nunc, Germany) at 37 ◦C for 3 h to enable a clotting. The transwells were hung
into a carrier plate and applied to the hTLCs in experimental medium, resulting in a concentration of
10% (v/v) blood products (Figure 6). All stimulations were performed in triplicates. After incubation
of the cells with the blood products for five days at 37 ◦C the inserts were carefully removed from the
cells and cell viability was tested again. Afterward, the RNA was isolated with the NucleoSpin RNA
Kit (Macherey-Nagel, Germany).
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4.8. Gene Expression Analysis
RNA quantity and purity was analyzed with the Nanodrop ND1000 system. A total of 100 ng
RNA were transcribed into cDNA with the qScript cDNA Supermix (Quanta Biosciences, Beverly,
MA, USA). For gene expression analysis, 1.25 ng of cDNA was used as PCR template. Quantitative
Real-Time PCR (qPCR) was performed with the SyBr Green Mastermix (Quanta biosciences) according
to the manufacturer’s instructions using the Light Cycler 480 System (Roche, Mannheim, Germany).
All primer sequences were designed using Primer 3 software (Freeware; Available online: http:
//frodo.wi.mit.edu/primer3), and were produced by Tib Molbiol, Berlin, Germany (Primer sequences
see Table 1). All primers were tested for amplification efficiency and the ∆Ct method with efficiency
correction was used to calculate the relative gene expression to the reference gene 18S rRNA.
Table 1. Primer sequences.
Gene Accession No. Primer Sequence Size (bp)
18S RNA NM_022551
Forward: 5′ CGGAAAATAGCCTTTGCCATC 3′
107Reverse: 5′ AGTTCTCCCGCCCTCTTGGT 3′
Col1A1 NM_000088.3
Forward: 5′ TGA CCT CAA GAT GTG CCA CT 3′
197Reverse: 5′ ACC AGA CAT GCC TCT TGT CC 3′
Col3A1 NM_000090.3
Forward: 5′ GCT GGC ATC AAA GGA CAT CG 3′
199Reverse: 5′ TGT TAC CTC GAG GCC CTG GT 3′
IL-1β NM_000576
Forward: 5′ TCC AGG AGA ATG ACC TGA GC 3′
111Reverse: 5′ GTG ATC GTA CAG GTG CAT CG 3′
IL-6 NM_000600
Forward: 5′ TGA GGA GAC TTG CCT GGT GA 3′
188Reverse: 5′ TTG GGT CAG GGG TGG TTA TT 3′
IL-10 NM_000572
Forward: 5′ TGA GAA CAG CTG CAC CCA CT 3′
164Reverse: 5′ GGC AAC CCA GGT AAC CCT TA 3′
TNF-α NM_000594
Forward: 5′ AGC CCA TGT TGT AGC AAA CC 3′
133Reverse: 5′ GAG GTA CAG GCC CTC TGA TG 3′
COX1 NM_001271368
Forward: 5′ CGT GTG TGT GAC CTG CTG AA 3′
193Reverse: 5′ TGC GGT ATT GGA ACT GGA CA 3′
COX2 NM_000963
Forward: 5′ TAG AGC CCT TCC TCC TGT GC 3′
129Reverse: 5′ TGG GGA TCA GGG ATG AAC TT3′
HGF NM_000601
Forward: 5′ CGC TGG GAG TAC TGT GCA AT 3′
116Reverse: 5′ GCC CCT GTA GCC TTC TCC TT 3′
MMP-1 NM_002421.3
Forward: 5′ CAC GCC AGA TTT GCC AAG AG 3′
148Reverse: 5′ GTC CCG ATG ATC TCC CCT GA 3′
MMP-2 NM_004530
Forward: 5′ TGG ATG ATG CCT TTG CTC GT 3′
156Reverse: 5′ CCA GGA GTC CGT CCT TAC CG 3′
MMP-9 NM_004994.2
Forward: 5′ GGG ACG CAG ACA TCG TCA TC3′
150Reverse: 5′ GGG ACC ACA ACT CGT CAT CG 3′
MMP-13 NM_002427.3
Forward: 5′ CCT TCC CAG TGG TGG TGA TG 3′
144Reverse: 5′ CGG AGC CTC TCA GTC ATG GA 3′
SCX Quantitect primerAssay Hs_SCXB_2_SG Not available
4.9. Statistics
Statistical analysis was performed using SPSS 20 (IBM, Armonk, NY, USA). Data are presented
as boxplots with median and 25% and 75% percentiles and the outliners marked as stars or
circles. The Kruskal–Wallis Test was used to determine significant differences between all groups
and the Mann–Whitney U test was used to evaluate differences between two groups followed
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by Bonferroni-Holm-Correction to adjust the p-value. Statistical significances are given as exact
significances with # marking differences to the HS control and a spanning line indicating differences
between the blood product groups. Additionally, a Spearmans Rho correlation (rs) analysis was
performed, and correlations above rs = 0.5 were considered.
5. Conclusions
Taken together, the overall results demonstrate no clear positive stimulatory effect of the different
blood products on tendon cell biology due to the increase in pro-inflammatory cytokine IL-1β and
matrix degrading enzyme MMP-1 and a decrease in the tendon marker SCX. This might partially be
a reason for the weak outcome in clinical practice. AlloPL seems to have the best effect by strongly
increasing Col1A1 expression and the pain antagonist HGF and decreasing the pain marker COX1.
AlloPL is a pooled lysate of different donors, which might account for the positive findings. Therefore,
pooled and well-characterized platelet lysates could be the future for tendon tissue regeneration.
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